BioPharma Dive May 26, 2026 SR One’s Simeon George on how China is rewriting biotech’s venture playbook
BioPharma Dive May 21, 2026 BioMarin notches win in study that could expand use of top-selling medicine
BioPharma Dive May 20, 2026 After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
BioPharma Dive May 20, 2026 Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update